Effects of COMT, DRD2, BDNF, and APOE genotypic variation on treatment efficacy and cognitive side effects of electroconvulsive therapy

Journal of ECT

Volumn 31, Issue 2, 2015, Pages 129-135

  Bousman, Chad A ^a   Katalinic, Natalie ^b   Martin, Donel M ^b   Smith, Deidre J ^a   Ingram, Anna ^c   Dowling, Nathan ^a   Ng, Chee ^a   Loo, Colleen K ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

cognition; ECT; gene; remission; response

Indexed keywords

APOENZYME; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; DOPAMINE 2 RECEPTOR; APOLIPOPROTEIN E; COMT PROTEIN, HUMAN; DRD2 PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; COGNITION; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAPHY; EXECUTIVE FUNCTION; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MENTAL CONCENTRATION; MULTICENTER STUDY (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SEIZURE THRESHOLD; ADVERSE EFFECTS; ALLELE; COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; GENETIC POLYMORPHISM; GENETIC VARIATION; GENETICS; HOSPITAL PATIENT; MEMORY DISORDERS; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PROCEDURES; PROSPECTIVE STUDY; PSYCHOLOGY; TREATMENT OUTCOME;

ALLELES; APOLIPOPROTEINS E; BRAIN-DERIVED NEUROTROPHIC FACTOR; CATECHOL O-METHYLTRANSFERASE; COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; ELECTROCONVULSIVE THERAPY; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; INPATIENTS; MALE; MEMORY DISORDERS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RECEPTORS, DOPAMINE D2; TREATMENT OUTCOME;

EID: 84930398881     PISSN: 10950680     EISSN: 15334112     Source Type: Journal    
DOI: 10.1097/YCT.0000000000000170     Document Type: Article

References (52)

1. Merkl A, Heuser I, Bajbouj M. Antidepressant electroconvulsive therapy: mechanism of action, recent advances and limitations. Exp Neurol. 2009;219:20-26.
2. Heijnen WT, Birkenhager TK, Wierdsma AI, et al. Antidepressant pharmacotherapy failure and response to subsequent electroconvulsive therapy: a meta-analysis. J Clin Psychopharmacol. 2010;30:616-619.
3. Sackeim HA, Prudic J, Fuller R, et al. The cognitive effects of electroconvulsive therapy in community settings. Neuropsychopharmacology. 2007;32:244-254.
4. Verwijk E, Comijs HC, Kok RM, et al. Neurocognitive effects after brief pulse and ultrabrief pulse unilateral electroconvulsive therapy for major depression: a review. J Affect Disord. 2012;140:233-243.
5. Ingram A, Saling MM, Schweitzer I. Cognitive side effects of brief pulse electroconvulsive therapy: a review. J ECT. 2008;24:3-9.
6. Loo CK, Mahon M, Katalinic N, et al. Predictors of response to ultrabrief right unilateral electroconvulsive therapy. J Affect Disord. 2011;130:192-197.
7. Kindler S, Shapira B, Hadjez J, et al. Factors influencing response to bilateral electroconvulsive therapy in major depression. Convuls Ther. 1991;7:245-254.
8. Prudic J, Haskett RF, Mulsant B, et al. Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry. 1996;153:985-992.
9. Dombrovski AY, Mulsant BH, Haskett RF, et al. Predictors of remission after electroconvulsive therapy in unipolar major depression. J Clin Psychiatry. 2005;66:1043-1049.
10. Fraser RM, Glass IB. Unilateral and bilateral ECT in elderly patients. A comparative study. Acta Psychiatr Scand. 1980;62:13-31.
11. Sobin C, Sackeim HA, Prudic J, et al. Predictors of retrograde amnesia following ECT. Am J Psychiatry. 1995;152:995-1001.
12. van Waarde JA, van Oudheusden LJ, Heslinga OB, et al. Patient, treatment, and anatomical predictors of outcome in electroconvulsive therapy: a prospective study. J ECT. 2013;29:113-121.
13. Viikki ML, Jarventausta K, Leinonen E, et al. BDNF polymorphism rs11030101 is associated with the efficacy of electroconvulsive therapy in treatment-resistant depression. Psychiatr Genet. 2013;23:134-136.
14. Anttila S, Huuhka K, Huuhka M, et al. Catechol-O-methyltransferase (COMT) polymorphisms predict treatment response in electroconvulsive therapy. Pharmacogenomics J. 2008;8:113-116.
15. Domschke K, Zavorotnyy M, Diemer J, et al. COMT Val158Met influence on electroconvulsive therapy response in major depression. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:286-290.
16. Huuhka K, Anttila S, Huuhka M, et al. Dopamine 2 receptor C957T and catechol-O-methyltransferase Val158Met polymorphisms are associated with treatment response in electroconvulsive therapy. Neurosci Lett. 2008;448:79-83.
17. Fisman M, Rabheru K, Hegele RA, et al. Apolipoprotein E polymorphism and response to electroconvulsive therapy. J ECT. 2001;17:11-14.
18. Hariri AR, Goldberg TE, Mattay VS, et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and predicts memory performance. J Neurosci. 2003;23:6690-6694.
19. Raz N, Rodrigue KM, Kennedy KM, et al. Genetic and vascular modifiers of age-sensitive cognitive skills: effects of COMT, BDNF, ApoE, and hypertension. Neuropsychology. 2009;23:105-116.
20. Reinvang I, Winjevoll IL, Rootwelt H, et al. Working memory deficits in healthy APOE epsilon 4 carriers. Neuropsychologia. 2010;48:566-573.
21. Xu H, Kellendonk CB, Simpson EH, et al. DRD2 C957T polymorphism interacts with the COMT Val158Met polymorphism in human working memory ability. 2007;90:104-107.
22. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
23. Meador KJ, Moore EE, Nichols ME, et al. The role of cholinergic systems in visuospatial processing and memory. J Clin Exp Neuropsychol. 1993;15:832-842.
24. Benedict RHB, Schretlen D, Groninger L, et al. Hopkins Verbal Learning Test Revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol. 1998;12:43-55.
25. Benton AL, Hamsher K. Multilingual Aphasia Examination. Iowa City, IA: University of Iowa; 1976.
26. Spreen O, Strauss EA, eds. Compendium of Neuropsychological Tests. 2nd ed. New York, NY: Oxford University Press; 1998.
27. Woodcock R, Johnson M. Woodcock-Johnson Psycho-Educational Battery-Revised. Chicago, IL: Riverside; 1989.
28. Smith A. Symbol Digit Modalities Test. Los Angeles, CA: Western Psychological Services; 1991.
29. McElhiney M, Moody B, Sackeim H. The Autobiographical Memory Interview-Short Form, Version 3. New York, NY: New York State Psychiatric Institute; 2001.
30. Nelson HE, Willison JR. The National Adult Reading Test Manual. 2nd ed. Windsor, England: NFER-Nelson; 1991.
31. Wechsler D. Wechsler Test of Adult Readng (WTAR). San Antonio, TX: The Psychological Corporation; 2001.
32. Chen J, Lipska BK, Halim N, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortemhuman brain. Am J Hum Genet. 2004;75:807-821.
33. Egan MF, Kojima M, Callicott JH, et al. The BDNF Val66Met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112:257-269.
34. Hashimoto T, Serrano-Pozo A, Hori Y, et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide. J Neurosci. 2012;32:15181-15192.
35. Hirvonen MM, Laakso A, Nagren K, et al. C957T polymorphism of dopamine D2 receptor gene affects striatal DRD2 in vivo availability by changing the receptor affinity. Synapse. 2009;63:907-912.
36. Gaunt TR, Rodriguez S, Day IN. Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool 'CubeX'. BMC Bioinformatics. 2007;8:428.
37. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986;51:1173-1182.
38. Harrison PJ, Tunbridge EM. Catechol-O-methyltransferase (COMT): a gene contributing to sex differences in brain function, and to sexual dimorphism in the predisposition to psychiatric disorders. Neuropsychopharmacology. 2008;33:3037-3045.
39. Tunbridge EM, Harrison PJ, Weinberger DR. Catechol-O-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry. 2006;60:141-151.
40. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry. 2007;64:327-337.
41. Mann JJ. Neurobiological correlates of the antidepressant action of electroconvulsive therapy. J ECT. 1998;14:172-180.
42. Wahlund B, von Rosen D. ECT of major depressed patients in relation to biological and clinical variables: a brief overview. Neuropsychopharmacology. 2003;28(suppl 1):S21-S26.
43. Xie T, Ho SL, Ramsden D. Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol Pharmacol. 1999;56:31-38.
44. Huuhka K, Anttila S, Huuhka M, et al. Brain-derived neurotrophic factor (BDNF) polymorphisms G196A and C270T are not associated with response to electroconvulsive therapy in major depressive disorder. Eur Arch Psychiatry Clin Neurosci. 2007;257:31-35.
45. Szeszko PR, Lipsky R, Mentschel C, et al. Brain-derived neurotrophic factor val66met polymorphism and volume of the hippocampal formation. Mol Psychiatry. 2005;10:631-636.
46. Dempster E, Toulopoulou T, McDonald C, et al. Association between BDNF val66 met genotype and episodic memory. Am J Med Genet B Neuropsychiatr Genet. 2005;134B:73-75.
47. 2 and catechol-O-methyl transferase genes and cognitive function. Behav Genet. 2010;40:630-638.
48. Rodriguez-Jimenez R, Hoenicka J, Jimenez-Arriero MA, et al. Performance in the Wisconsin Card Sorting Test and the C957T polymorphism of the DRD2 gene in healthy volunteers. Neuropsychobiology. 2006;54:166-170.
49. Caselli RJ, Reiman EM, Osborne D, et al. Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele. Neurology. 2004;62:1990-1995.
50. Mayeux R, Small SA, Tang M, et al. Memory performance in healthy elderly without Alzheimer's disease: effects of time and apolipoprotein-E. Neurobiol Aging. 2001;22:683-689.
51. Lopez OL, Jagust WJ, Dulberg C, et al. Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: part 2. Arch Neurol. 2003;60:1394-1399.
52. Loo CK, Garfield JB, Katalinic N, et al. Speed of response in ultrabrief and brief pulse width right unilateral ECT. Int J Neuropsychopharmacol. 2013;16:755-761.